| Current Price | $0.29 | Mkt Cap | $3.7M |
|---|---|---|---|
| Open | $0.30 | P/E Ratio | -0.15 |
| Prev. Close | $0.29 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.28 - $0.30 | Volume | 1,109 |
| 52-Wk Range | $0.25 - $1.17 | Avg. Daily Vol. | 178,362 |
A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
| Current Price | $0.29 | Mkt Cap | $3.7M |
|---|---|---|---|
| Open | $0.30 | P/E Ratio | -0.15 |
| Prev. Close | $0.29 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.28 - $0.30 | Volume | 1,109 |
| 52-Wk Range | $0.25 - $1.17 | Avg. Daily Vol. | 178,362 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about CYCC.
Recs
oscillation
(70.35)
Submitted: 6/1/2015 1:40:33 AM :
Start Price:
$8.64
NASDAQ:CYCC Score:
-211.20
nev
Recs
UnstableEnabled
(< 20)
Submitted: 12/21/2013 3:30:17 AM :
Start Price:
$44.94
NASDAQ:CYCC Score:
-248.66
A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.
It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.
Sorely depressed, any good new will cause the stock to surge upward.
Recs
toegar2000
(< 20)
Submitted: 3/2/2013 10:25:20 AM :
Start Price:
$64.19
NASDAQ:CYCC Score:
-299.20
Looks good IMO
Find the members with the highest scoring picks in CYCC.
longtermgrowth09 (60.31) Score: +404.09
The Score Leader is the player with the highest score across all their picks in CYCC.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| longtermgrowth09 | 60.31 | 8/3/2010 |
|
5Y | $137.26 | -99.79% | +304.30% | +404.09 | 0 Comment | |
| mrtofoo | 22.94 | 1/7/2008 |
|
5Y | $425.66 | -99.93% | +236.64% | +336.58 | 0 Comment | |
| MFBurritoSquat | 68.73 |
|
|
1Y | $37.47 | -99.22% | +221.34% | +320.56 | 0 Comment | |
| bluebare | 26.33 | 12/7/2012 |
|
5Y | $75.63 | -99.62% | +220.21% | +319.82 | 0 Comment | |
| imrhh | < 20 | 5/7/2007 |
|
3M | $637.27 | -99.95% | +218.65% | +318.61 | 2 Comments | |
| klaracat | 35.96 | 10/22/2012 |
|
5Y | $60.93 | -99.52% | +217.68% | +317.20 | 0 Comment | |
| IdahoInvestor | 99.65 | 8/13/2015 |
|
5Y | $7.18 | -95.95% | +117.87% | +213.82 | 0 Comment | |
| GenericMind5885 | 96.73 | 2/27/2015 |
|
5Y | $17.97 | -98.38% | +115.28% | +213.66 | 0 Comment | |
| iPittytheFool | 51.42 | 10/10/2016 |
|
5Y | $5.47 | -94.68% | +110.39% | +205.07 | 0 Comment | |
| portefeuille2 | 98.44 | 4/29/2019 |
|
5Y | $0.68 | -57.49% | +54.94% | -112.43 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
